Mouse model confirms early energy loss precedes brain cell death . A groundbreaking study published in Proceedings of the ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with ...

In this video, Khalaf Bushara, MD, FRCP, discusses therapies in the pipeline that show promise for the treatment of Friedriech's ataxia.

SKYCLARYS® (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older in over 40 countries ...

Omaveloxolone is currently marketed under the brand name SKYCLARYS ® for the treatment of adults and adolescents aged 16 years and older affected by Friedreich ataxia CAMBRIDGE, Mass., June 18 ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.

Reata says its Nrf2 activator omaveloxolone hits the mark in Friedrich’s ataxia just days after buying back ... Treatment with a 150 mg daily oral dose of omaveloxolone over 48 weeks in the ...